GLP-1– tag –
-
CVS Caremark Expands Access to Eli Lilly’s Obesity Portfolio: Reinstates Zepbound, Adds Foundayo
FirstWord Pharma USA Overview CVS Caremark announced it will reinstate coverage for Eli Lilly's injectable weight-loss medication Zepbound (tirzepatide) and add the newly launched oral GLP-1 drug Foundayo (orforglipron) to its standard c... -
Eli Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company (PRNewswire), Healthline, BioPharma Dive, The Guardian, BioSpace, GlobalData USA Overview Eli Lilly's triple hormone receptor agonist, retatrutide (GIP, GLP-1, and glucagon), demonstrated powerful and clinically mea... -
Key FDA Approvals Anticipated for GLP-1 Pipeline in May 2026 Update
Prime Therapeutics - Portal USA Overview Four significant FDA approval decisions for GLP-1 related medications are expected in 2026, marking critical advancements in metabolic disease management. Eli Lilly's injectable Mounjaro is antici... -
Beyond GLP-1: Next-Gen Obesity Drug Race Accelerates with Multi-Agonist Therapies
The Elec Inc. South Korea Overview The race for next-generation obesity drugs is expanding beyond GLP-1 injections into multi-agonist therapies targeting multiple hormones. Eli Lilly's Retatrutide, a triple agonist for GLP-1, GIP, and gl... -
GLP-1 Gene Therapy Enters First Human Clinical Trials; Endometriosis Poised for First Disease-Modifying Treatment
DDN Magazine USA Overview This week's DDN Weekly Rundown reports that GLP-1 gene therapy has advanced into its first human clinical trials, alongside the potential emergence of the first disease-modifying therapy for endometriosis. The e... -
GLP-1 Drug Manufacturing Surges: CDMOs Scale Peptide Synthesis, Driving Technology Transfer
IntuitionLabs USA Overview Driven by soaring GLP-1 demand, Contract Development and Manufacturing Organizations (CDMOs) are rapidly expanding peptide synthesis capabilities. Industry reports project the GLP-1 peptide CDMO market to grow ... -
Lilly’s Retatrutide Achieves Unprecedented Weight Loss in Pivotal Phase 3 Obesity Trial
Eli Lilly and Company USA Overview Eli Lilly's triple-agonist retatrutide, targeting GIP, GLP-1, and glucagon receptors, demonstrated powerful efficacy in its pivotal Phase 3 TRIUMPH-1 trial for obesity. Patients receiving the highest do... -
EktaH Reveals Promising Early-Phase Data for Novel Obesity Drug NKS-3, Targeting Fat Loss with Muscle Retention
European Biotechnology Global Overview EktaH has released early clinical trial data for its novel obesity drug candidate, NKS-3, demonstrating promising results in both fat reduction and muscle preservation. Preclinical mouse data indica... -
Eli Lilly’s Oral Orforglipron Effective in Older Adults with Obesity, Receives FDA Approval as Non-Peptide GLP-1 Offering Dosing Flexibility
Medscape USA Overview Eli Lilly's once-daily oral GLP-1 receptor agonist, orforglipron (Foundayo), demonstrated clinically significant weight loss and a favorable safety profile in obese adults aged 65 and older, similar to younger popul... -
Precision Peptide Company (BPC) Pioneers Advanced Peptide Manufacturing with Continuous Flow Synthesis and AI Integration to Meet GLP-1 Demand
Bitget アイルランド Overview Precision Peptide Company Inc. (BPC) is emerging as a critical CDMO partner for GLP-1 agonists, oncology vaccines, and targeted radiopharmaceuticals. Their proprietary "Flow-Peptide" continuous flow synthesis...
